You just opened a lipid metabolism question…and every answer choice looks almost right. Welcome to HMG‑CoA reductase: the rate-limiting step of cholesterol synthesis, a favorite for Step-style vignettes because it connects biochemistry ↔ pharmacology ↔ endocrine/metabolic disease. The trick is not just knowing the correct answer—it’s knowing why the other choices are wrong.
Tag: Biochemistry > Lipid Metabolism
The Clinical Vignette (Q‑Bank Style)
A 56-year-old man with type 2 diabetes and hypertension is started on a new medication after his lipid panel shows LDL cholesterol of 196 mg/dL. Two months later, his LDL is markedly decreased. He reports new diffuse muscle aches but has no weakness. Labs show mildly elevated CK. His physician explains that the medication inhibits the rate-limiting step in hepatic cholesterol synthesis.
Which of the following enzymes is most directly inhibited?
A. HMG‑CoA reductase
B. HMG‑CoA synthase
C. LDL receptor
D. ACAT (acyl‑CoA:cholesterol acyltransferase)
E. Cholesterol 7α‑hydroxylase
Correct Answer: A. HMG‑CoA reductase
What it does (the core concept)
HMG‑CoA reductase catalyzes the rate-limiting step of cholesterol synthesis in the cytosol:
- Location: cytosol (associated with smooth ER membrane)
- Tissue emphasis: liver (high yield), also many other tissues
- Cofactor: uses NADPH (cholesterol synthesis is an anabolic pathway—think NADPH)
- Regulation: heavily regulated by sterol levels, hormones, and statins
Why the vignette points here
- Marked LDL reduction + myalgias + mild CK elevation screams statin.
- Statins are competitive inhibitors of HMG‑CoA reductase → ↓ cholesterol synthesis → ↓ hepatic cholesterol → upregulates LDL receptors → ↑ LDL clearance from blood.
High-yield statin facts (Step 1 + Step 2)
- Main lipid effect: ↓ LDL (biggest), mild ↓ TG, mild ↑ HDL
- Adverse effects:
- Myopathy/myalgias (risk ↑ with interacting drugs)
- Hepatotoxicity (check AST/ALT if symptomatic)
- Pregnancy: contraindicated (teratogenic risk; conceptually avoid cholesterol synthesis blockade)
- Drug interactions: classically increased myopathy risk with agents that raise statin levels (you’ll often see “combo therapy” cues)
The Distractors (Why Each One Matters)
B. HMG‑CoA synthase (Wrong—but important)
Why it’s tempting: It sounds almost identical and sits right upstream.
What it actually does:
- Converts acetyl‑CoA → HMG‑CoA
- Exists in two locations, which is the classic testable point:
- Mitochondrial HMG‑CoA synthase: ketogenesis (liver mitochondria)
- Cytosolic HMG‑CoA synthase: cholesterol synthesis pathway (upstream of reductase)
Why it’s wrong here: Statins inhibit HMG‑CoA reductase, not synthase.
Board tip:
If the question mentions fasting, DKA, ketones → think mitochondrial HMG‑CoA synthase.
If it mentions LDL lowering + myalgias → think HMG‑CoA reductase.
C. LDL receptor (Wrong target; right downstream concept)
Why it’s tempting: Statins do affect LDL receptors…just not by direct inhibition.
Key concept: Statins increase hepatic LDL receptor expression.
Mechanism chain:
- Statin → ↓ hepatic cholesterol synthesis
- Liver senses low intracellular cholesterol → activates SREBP signaling
- ↑ LDL receptor expression on hepatocytes → ↑ LDL uptake → ↓ plasma LDL
Why it’s wrong: The question asks for what is directly inhibited. LDL receptors are upregulated, not inhibited.
High-yield clinical tie-in:
- Familial hypercholesterolemia (LDLR mutation) → high LDL despite lifestyle; tendon xanthomas, premature CAD.
- These patients may have a blunted response to statins because receptor function is impaired.
D. ACAT (acyl‑CoA:cholesterol acyltransferase) (Wrong enzyme, different purpose)
What ACAT does: Esterifies cholesterol for storage inside cells:
- Converts cholesterol → cholesteryl esters
- Helps package cholesterol for storage (e.g., in lipid droplets) and contributes to intracellular cholesterol handling.
Where students get tripped up: Confusing ACAT with LCAT.
ACAT vs LCAT (very testable)
| Enzyme | Location | Function | High-yield association |
|---|---|---|---|
| ACAT | Inside cells (esp. liver, intestine) | Cholesterol storage (cholesteryl ester formation) | Intracellular cholesterol handling |
| LCAT | In plasma, on HDL | Cholesterol esterification on HDL (HDL maturation) | Low LCAT → abnormal HDL, impaired reverse cholesterol transport |
Why ACAT is wrong here: Statins do not work by blocking cholesterol esterification; they block cholesterol synthesis at the rate-limiting step.
E. Cholesterol 7α‑hydroxylase (Wrong—but an extremely high-yield distractor)
What it does: Catalyzes the rate-limiting step in bile acid synthesis from cholesterol.
- Cholesterol → bile acids (major route for cholesterol elimination)
- Upregulated by cholesterol
- Downregulated by bile acids (negative feedback)
Why it’s tempting: Another “rate-limiting cholesterol-related enzyme.”
Why it’s wrong: The vignette is about decreasing cholesterol synthesis (statin), not increasing cholesterol disposal through bile acid production.
Clinical integration (frequent Step logic):
- Bile acid resins (cholestyramine, colestipol, colesevelam) bind bile acids in gut → force liver to make more bile acids → uses cholesterol → upregulates LDL receptors → ↓ LDL.
- That mechanism hinges on bile acid recycling and indirectly relates to 7α‑hydroxylase, but it’s not the enzyme “directly inhibited” in a statin vignette.
Put It Together: A 15-Second Mental Map
Cholesterol synthesis (the “statin lane”)
- Rate-limiting: HMG‑CoA reductase
- Location: cytosol/smooth ER
- Cofactor: NADPH
- Drug: statins → ↓ cholesterol synthesis → ↑ LDL receptors → ↓ LDL
Ketone synthesis (the “fasting/DKA lane”)
- Key enzyme: mitochondrial HMG‑CoA synthase
- Location: liver mitochondria
- Context: fasting, uncontrolled diabetes, alcoholic ketoacidosis
Bile acids (the “cholesterol disposal lane”)
- Rate-limiting: cholesterol 7α‑hydroxylase
- Drug tie-in: bile acid sequestrants (not statins)
High-Yield Test Triggers (How Questions Signal HMG‑CoA Reductase)
Look for:
- LDL reduction as primary effect
- Myalgias ± ↑ CK
- Mention of competitive inhibitor of cholesterol synthesis
- Phrases like “rate-limiting step of cholesterol synthesis”
- Hepatic focus: “increased LDL receptor expression”
Avoid common traps:
- “Rate-limiting step” could also refer to cholesterol 7α‑hydroxylase (bile acid synthesis) → check the clinical context.
- “HMG‑CoA…” could refer to ketogenesis (mitochondrial HMG‑CoA synthase/lyase) → look for ketones/fasting/DKA.
Rapid-Fire Practice: One-Liners You Should Be Able to Say
- HMG‑CoA reductase: rate-limiting cholesterol synthesis; inhibited by statins; uses NADPH; cytosol/SER.
- Statins lower LDL primarily by upregulating LDL receptors after reducing hepatic cholesterol.
- HMG‑CoA synthase (mitochondrial) is for ketone body synthesis, not the statin target.
- Cholesterol 7α‑hydroxylase is rate-limiting for bile acid synthesis.
- ACAT stores cholesterol inside cells; LCAT esterifies cholesterol on HDL in plasma.
Frequently Asked Questions
What enzyme do statins directly inhibit to lower LDL cholesterol?
Statins directly inhibit HMG-CoA reductase. This enzyme catalyzes the rate-limiting step of cholesterol synthesis, converting HMG-CoA to mevalonate in the cytosol. By decreasing hepatic cholesterol synthesis, statins lower intracellular cholesterol, which leads the liver to upregulate LDL receptors and clear more LDL from the blood.
Why do statins increase LDL receptor expression if they inhibit cholesterol synthesis?
Statins increase LDL receptor expression because lowering hepatic cholesterol triggers a compensatory response in the liver. When intracellular cholesterol falls, SREBP signaling is activated, which increases LDL receptor expression on hepatocytes. The result is increased LDL uptake from the bloodstream and a marked reduction in plasma LDL levels.
How do you tell HMG-CoA reductase from HMG-CoA synthase on a lipid metabolism question?
The key difference is function and context. HMG-CoA reductase is the rate-limiting enzyme of cholesterol synthesis and is the direct target of statins, so clues like marked LDL reduction, myalgias, and mild CK elevation point there. HMG-CoA synthase is upstream and exists in cytosolic and mitochondrial forms, with the mitochondrial form classically tied to ketogenesis, fasting, DKA, and ketones.
How do you distinguish ACAT from LCAT for exam questions?
ACAT works inside cells and esterifies cholesterol for storage as cholesteryl esters, especially in tissues like the liver and intestine. LCAT works in plasma on HDL and esterifies cholesterol as part of HDL maturation and reverse cholesterol transport. This distinction matters because statins do not block cholesterol esterification; they block cholesterol synthesis at HMG-CoA reductase.
Why is cholesterol 7α-hydroxylase the wrong answer in a statin vignette?
Cholesterol 7α-hydroxylase is wrong because it is the rate-limiting enzyme in bile acid synthesis, not cholesterol synthesis. A statin vignette is about direct inhibition of the rate-limiting step of hepatic cholesterol production, which is HMG-CoA reductase. Cholesterol 7α-hydroxylase is more relevant to bile acid formation and the logic behind bile acid resins.